Paul Blake., Chief Development Officer at Oxford BioMedica, holds 2.62M shares in Oxford BioMedica (Ticker: OXBDF), holds 70.35K shares in Aeterna Zentaris (Ticker: AEZS). Most recently, Paul Blake. Bought ― shares of Oxford BioMedica on Mar 16, 2015 for an estimated value of 10.00K.